Clinical study of Wangbi Tablets combined with tofacitinib in treatment of rheumatoid arthritis
Objective To explore the clinical efficacy of Wangbi Tablets combined with tofacitinib in treatment of rheumatoid arthritis. Methods A total of 116 patients with rheumatoid arthritis admitted to the Second People's Hospital of Liaocheng from September2022 to August 2023 were selected. SPSS 27.0 statistical software package was used to generate a random number table,and randomly divided into a control group (58 cases) and a treatment group (58 cases) according to 1:1. Patients in the control group were po administered with Tofacitinib Citrate Tablets,5 mg/time,twice daily. Patients in the treatment group were po administered with Wangbi Tablets on the basis of the control group,4 tablets/time,three times daily. Both groups were treated for 12 weeks. The clinical efficacy of the two groups was observed after 4,8 and 12 weeks of treatment. The changes of clinical manifestations,28 joint disease activity (DAS28-CRP and DAS28-ESR) scores,rheumatoid arthritis Self-efficacy Scale (RASE) scores,36 health survey summary Form (SF-36) scores,whole blood neutrophil to lymphocyte ratio (NLR) and serum C-reactive protein (CRP),interleukin (IL)-6,interferon-γ (IFN-γ),and IL-10 in two groups were compared before and after treatment for changed. Results After 4 and 8 weeks of treatment,the total effective rate of the treatment group was 72.41％ and 86.21％,respectively,which had no statistical significance compared with 67.24％ and 75.86％ of the control group. After 12 weeks of treatment,the total effective rate of treatment group was 94.83％,which was significantly higher than that of control group (82.76％) (P<0.05). After treatment,joint pain score,swelling score,adverse flexion and extension score,morning stiffness score and joint tenderness score in 2 groups were significantly lower than before treatment (P<0.05). After treatment,the clinical performance score of the treatment group was significantly lower than that of the control group (P<0.05). After treatment,DAS28-CRP score and DAS28-ESR score were significantly decreased,but RASE score and SF-36 score were significantly increased in both groups (P<0.05). After treatment,DAS28 score,RASE score and SF-36 score in the treatment group were better than those in the control group (P<0.05). After treatment,NLR,CRP,IL-6,IFN-γ and IL-10 were significantly decreased in both groups (P<0.05). After treatment,the inflammation index in the treatment group was lower than that in the control group (P<0.05). Conclusion Wangbi Tablets combined with tofacitinib has a definite effect in treatment of rheumatoid arthritis,and can effectively promote the reduction of clinical manifestations and disease activity,further alleviate the inflammatory damage of the body,improve the self-efficacy and quality of life of patients.
NETL
NSTL
万方数据
